Business Description
Contineum Therapeutics is a San Diego-based clinical-stage company focused on developing small-molecule drugs to treat neurological, inflammatory, and immune system disorders. Its lead drug candidate, PIPE-791, targets a specific receptor in the brain and is being studied as a potential treatment for idiopathic pulmonary fibrosis and chronic pain. The company is also advancing PIPE-307, which works through a different receptor mechanism and is being evaluated for depression and relapsing-remitting multiple sclerosis. Formerly known as Pipeline Therapeutics, the company adopted its current name in November 2023 and has been operating since 2009.
